Journal article
Resistance mechanism for ibrutinib in marginal zone lymphoma
Blood advances, Vol.3(4), pp.500-502
02/13/2019
DOI: 10.1182/bloodadvances.2018029058
PMCID: PMC6391658
PMID: 30760464
Abstract
The molecular events leading to primary and acquired resistance to ibrutinib in marginal zone lymphoma have not been studied.
We describe the first case of MZL with acquired resistance to ibrutinib in which mutations in both
BTK
(C481S) and
PLCG2
are documented.
Details
- Title: Subtitle
- Resistance mechanism for ibrutinib in marginal zone lymphoma
- Creators
- Narendranath Epperla - The Ohio State UniversityArwa Y. Shana’ah - The Ohio State UniversityDan Jones - The Ohio State UniversityBeth A. Christian - The Ohio State UniversitySabarish Ayyappan - The Ohio State UniversityKami Maddocks - The Ohio State UniversityJennifer A. Woyach - The Ohio State University
- Resource Type
- Journal article
- Publication Details
- Blood advances, Vol.3(4), pp.500-502
- Publisher
- American Society of Hematology
- DOI
- 10.1182/bloodadvances.2018029058
- PMID
- 30760464
- PMCID
- PMC6391658
- ISSN
- 2473-9529
- eISSN
- 2473-9537
- Language
- English
- Date published
- 02/13/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984360052902771
Metrics
9 Record Views